Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07836283 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab

Name: Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab — clinical trial record (NCT07836283)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ThoracSPA

StatusNot Yet Recruiting

PhasePhase 3

SponsorUniversity Hospital, Rouen

Started2026-10-15

View on ClinicalTrials.gov ↗

University Hospital, Rouen

259 trials monitored

See all monitored trials

Psoriasis

418 trials monitored

See 17 trials at risk

Ankylosing Spondylitis

176 trials monitored

See 6 trials at risk

The primary objective is to demonstrate the superiority of BKZ (dual inhibition of IL-17A and IL-17F) on the ASAS40 response at 6 months compared to a reference treatment (ADA) in patients with active axial or predominantly axial SpA, bDMARD and/or JAKi naïve, with an inadequate response to NSAIDs, one of the main complaints of which being focused on ACW. Since the study is a pragmatic trial aiming at changing prescriptions, the treatment policy estimand strategy will be used

Trial Details

NCT Number	NCT07836283
Lead Sponsor	University Hospital, Rouen
Conditions	Axial or Predominantly Axial SpondyloArthritis With or Without Psoriasis
Enrollment	150 participants
Start Date	2026-10-15
Primary Completion	2030-04-15 (estimated)
Study Completion	2030-10-15 (estimated)
Updated on ClinicalTrials.gov	2026-09-23